236 related articles for article (PubMed ID: 7715873)
1. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users.
Robinson GM; Reynolds JN; Robinson BJ
N Z Med J; 1995 Mar; 108(996):103-5. PubMed ID: 7715873
[TBL] [Abstract][Full Text] [Related]
2. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
Kemp R; Miller J; Lungley S; Baker M
N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D
N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775
[TBL] [Abstract][Full Text] [Related]
4. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
5. [Risk factors for hepatitis C among injecting drug users in Oslo].
Dalgard O; Egeland A; Ervik R; Vilimas K; Skaug K; Steen TW
Tidsskr Nor Laegeforen; 2009 Jan; 129(2):101-4. PubMed ID: 19151801
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C prevalence and risk behavior of injecting drug users in Sydney: a continuing concern.
Habib SE; Lovejoy FH; Aspin C
Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):823-34. PubMed ID: 12041560
[TBL] [Abstract][Full Text] [Related]
7. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
8. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
[TBL] [Abstract][Full Text] [Related]
9. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users.
Brunton C; Kemp R; Raynel P; Harte D; Baker M
N Z Med J; 2000 Mar; 113(1106):98-101. PubMed ID: 10836310
[TBL] [Abstract][Full Text] [Related]
10. Irish injecting drug users and hepatitis C: the importance of the social context of injecting.
Smyth BP; Barry J; Keenan E
Int J Epidemiol; 2005 Feb; 34(1):166-72. PubMed ID: 15513970
[TBL] [Abstract][Full Text] [Related]
11. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
[TBL] [Abstract][Full Text] [Related]
12. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
13. [Prevalence of hepatitis B, hepatitis C and HIV among injecting drug users treated outpatiently and in therapeutic community in Brod-Posavina County, Croatia].
Kolovrat A; Jurisić I; Marić Z; Cvitković A
Acta Med Croatica; 2010 Oct; 64(4):287-96. PubMed ID: 21688612
[TBL] [Abstract][Full Text] [Related]
14. Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users.
Burt RD; Thiede H; Hagan H
Drug Alcohol Depend; 2009 Dec; 105(3):215-20. PubMed ID: 19720473
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
[TBL] [Abstract][Full Text] [Related]
16. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
17. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence of HIV and HCV among injecting drug users (IDUs) in Yunnan, China].
Li D; Zheng X; Zhang G
Zhonghua Liu Xing Bing Xue Za Zhi; 1994 Apr; 15(2):74-5. PubMed ID: 7522968
[TBL] [Abstract][Full Text] [Related]
19. Epidemiological and genetic analyses of Hepatitis C virus transmission among young/short- and long-term injecting drug users from Rio de Janeiro, Brazil.
Oliveira Mde L; Bastos FI; Telles PR; Hacker Mde A; Oliveira SA; Miguel JC; Yoshida CF
J Clin Virol; 2009 Mar; 44(3):200-6. PubMed ID: 19195927
[TBL] [Abstract][Full Text] [Related]
20. A cross-sectional study on factors including HIV testing and counselling determining unsafe injecting practices among injecting drug users of Manipur.
Sarkar S; Panda S; Sarkar K; Hangzo CZ; Bijaya L; Singh NY; Das N; Agarwal A; Chatterjee A; Deb BC
Indian J Public Health; 1995; 39(3):86-92. PubMed ID: 8690497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]